Avid Bioservices Inc (CDMO)

[md1225]

So to the same token bavituximab has already shown in a phase 2b trial to double MOS in 2nd line NSCLC.

First look in potential trial halt DMC recommends all patients receive bavituximab is the PR we should receive anyday.


http://seekingalpha.com/article/2953756-wall-streets-current-play-immunotherapy-of-cancer

Thanks Roy